"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."

Margaret Mead

Case report
peer-reviewed

Johnson and Johnson COVID-19 Vaccination Triggering Pheochromocytoma Multisystem Crisis



Abstract

Pheochromocytomas are rare tumors that may have variable presentations. The presentation may depend on the type of catecholamine secreted, whether there is a paraneoplastic syndrome or not, or some other factor which may not be well understood. One rare presentation is a pheochromocytoma multisystem crisis. Many of these tumors are asymptomatic and found incidentally, but some can be triggered after being previously dormant. In this case report, we describe the first case of pheochromocytoma multisystem crisis triggered by the Johnson and Johnson (J&J) coronavirus disease 2019 (COVID-19) vaccine. We describe a case of a 63-year-old Caucasian male who presented with intractable nausea, vomiting, dyspnea, watery diarrhea, chills, sweats, and heavy chest pain starting one day status post J&J COVID-19 vaccination. He had no symptoms prior to this and no significant past medical history besides daily marijuana use. During his hospital stay, he had persistent high fevers, respiratory failure, cardiogenic shock, cardiomyopathy, and labile blood pressure measurements. After a retroperitoneal ultrasound, he was found to have a 7 cm mass in the right adrenal gland with elevated chromogranin A, urine vanillylmandelic acid (VMA), and urinary 24-hour metanephrines to confirm the diagnosis of a pheochromocytoma.

Introduction

Pheochromocytomas are rare catecholamine-secreting tumors arising from the adrenal medulla. Almost all catecholamine-secreting tumors are benign and intra-adrenal, although some can be extra-adrenal and termed catecholamine-secreting paragangliomas [1-5]. Many pheochromocytomas are discovered incidentally on abdominal imaging for unrelated reasons, but symptomatic patients will commonly present with episodic headache, sweating, tachycardia, and paroxysmal hypertension [1,6,7]. The hypersecretion of one or combinations of norepinephrine, epinephrine, and dopamine causes the symptoms of pheochromocytomas [1]. An increase in central sympathetic activity can contribute as well [1]. Patients with tumors that only secrete epinephrine may present with episodic hypotension [8,9]. Pheochromocytomas in asymptomatic patients may be triggered by certain medications as will be discussed later.

A patient with pheochromocytoma multisystem crisis may have hypertension or hypotension, hyperthermia, mental status changes, and other organ dysfunction, similar to our patient's symptoms [10]. In addition, the rapid cyclical fluctuations of hypertension and hypotension along with his cardiomyopathy are also rare manifestations of the condition [11-13]. The mechanism for cyclical hypertension and hypotension is unknown, but fluid repletion and alpha-adrenergic antagonists may help [12,13]. The rarity of this presentation is magnified further by the fact that his condition was triggered by receiving the Johnson and Johnson (J&J) coronavirus disease 2019 (COVID-19) vaccine, an adverse event not previously reported. 

Coronaviruses are single-stranded, positive-sense, enveloped RNA viruses [14]. The COVID-19 virus is a variant of the coronavirus that causes severe respiratory disease and has caused a global pandemic [14]. Vaccines from different companies have been formulated to combat the virus, one of which being the J&J COVID-19 vaccine. This vaccine is a nonreplicating viral vector vaccine that uses genetically modified adenovirus to create a spike protein that the immune system will respond to [15]. Many people have different reactions to these vaccines, but none have been similar to our patient. 

Case Presentation

A 63-year-old Caucasian male with a history only significant for daily marijuana use received the J&J COVID-19 vaccine on May 7, 2021. One day later, he developed intractable nausea, vomiting, dyspnea, watery diarrhea, chills, sweats, and heavy chest pain. In the emergency department (ED), the patient was tachycardic at 120 beats per minute, hypoxic with oxygen 88% on room air, brain natriuretic peptide (BNP) 3421 pg/ml, elevated troponins at 1.29 ng/ml, procalcitonin 25 ng/ml, lactic acid 5.0 mmol/L, white blood cells 19 K/UL, thrombocytopenia at 101 K/UL, and creatinine 1.91 mg/dL. Initial chest X-ray showed bilateral airspace opacities consistent with atypical pneumonia. The patient was intubated because he was in severe respiratory distress with use of accessory muscles and decreased oxygen saturation. Ventilator settings are presented in Table 1

Ventilator Setting Value
Fraction of inspired oxygen (FiO2) 100%
Respiratory rate (RR) 16 breaths per minute 
Positive end-expiratory pressure (PEEP) 10 cm H20

Echo showed an ejection fraction (EF) of 25% with global hypokinesis and grade 3 diastolic dysfunction. A right heart catheterization was performed, showing severe pulmonary hypertension. An intra-aortic balloon pump was inserted, but his condition continued to decline, so a left-sided Impella device (Impella Cardiosystems AG, Aachen, Germany) was placed and milrinone and norepinephrine were started.

The patient was worked up for infectious causes and all were negative including two negative COVID-19 results, viral panel, blood cultures, urine cultures, sputum cultures, and urine legionella. A chest X-ray five days after presenting to the ED is shown below (Figure 1).

Throughout his nine-day hospital stay, he continued to have rapid cyclical fluctuations of hypertension (260s/130s) and hypotension (40s/20s), persistent fevers up to 40.2 °C, and acute respiratory distress syndrome (ARDS)-like picture. His other problems included acute tubular necrosis (ATN) from an acute kidney injury (AKI), hypernatremia, arterial catheter-associated thrombosis in mid left radial artery leading to gangrene of left 1st and 2nd digits, non-ST-elevation myocardial infarction (NSTEMI) with cardiogenic shock (on May 10, 2021, EF was 55% with no diastolic dysfunction), subclinical hyperthyroidism, and electroencephalogram (EEG) showed diffuse slowing, with no epileptiform activity. Echo on May 15, 2021 showed EF of 43% with mild global hypokinesis.

Neuroendocrine crisis was suspected, and the patient was worked up for pheochromocytoma and carcinoid syndrome (Table 2).

Study done Reference range Test results 
Metanephrine, Plasma <0.5 nmol/L 31.1 
Normetanephrine, Plasma <0.9 nmol/L 8.9  
Urine Vanillylmandelic acid 1.8 - 6.7 mg/day 153.9 
24-hour urine total metanephrines   140 - 785 ug/day 54,391 
24-hour urine Creatinine 1.0 - 2.0 gm/24h 1.1 
24-hour urine metanephrines 52 - 341 ug/day 36,144 
24-hour urine normetanephrines 88 - 444 ug/day 18,247
24-hour urine 5-Hydroxyindoleacetic acid 3-10 mg/24h  5.0

The results of retroperitoneal ultrasound are shown below (Figures 2-3).

The first step in the diagnosis of pheochromocytoma is to discontinue medications that may interfere with metanephrine levels such as norepinephrine. Due to our patient's labile blood pressure measurements, he was on and off of vasopressors (such as norepinephrine) and anti-hypertensive medications (nitroglycerin). The results of significantly elevated 24-hour urine fractionated metanephrines and catecholamines or elevated fractionated plasma metanephrines confirms the diagnosis of pheochromocytoma. Imaging with CT or MRI is done to localize the tumor. Our patient was not stable enough for these imaging tests and thus we had to do an ultrasound. There were no previous imaging studies on record for this patient or a family history that could explain the etiology of his tumor. 

The patient was transferred to the University of Michigan (U of M) hospital for mass resection on May 21, 2021. A CT was performed that day to confirm the ultrasound finding of a 7 cm heterogeneous right adrenal mass. The patient continued to suffer from acute hypoxemic respiratory failure and a tracheostomy was performed on June 07, 2021 due to prolonged intubation. His stay at U of M hospital was also complicated by episodes of non-sustained ventricular tachycardia (NSVT) that responded well to synchronized cardioversion. He was also placed on amiodarone. On June 18, 2021, an open right adrenalectomy was performed and on June 22, 2021, repeat plasma metanephrine was <0.2 nmol/L, and normetanephrine was 0.9 nmol/L. An echo performed on June 22, 2021 revealed a left ventricular EF of 63%, normal overall left ventricular systolic function, normal overall right ventricular systolic function, and no significant valvular dysfunction. Multiple upper and lower extremity deep vein thromboses (DVTs) were found on June 24, 2021. The patient was treated with blood thinners and stabilized for transfer to inpatient rehabilitation on July 02, 2021. The patient was then discharged on July 12, 2021 to stay with his sister. He has continued outpatient therapy and is now able to walk on his own and perform all of his activities of daily living independently. He will follow up with endocrine genetics for the etiology of his pheochromocytoma, cardiology, and physical medicine and rehabilitation. He will continue amiodarone for NSVT and rivaroxaban for the DVTs until the end of September 2021. The patient is doing very well overall. 

Discussion

Pheochromocytomas are rare tumors with an annual incidence of 0.8 per 100,000 person-years [16]. They are catecholamine-secreting tumors arising from chromaffin cells of the adrenal medulla. Almost all catecholamine-secreting tumors are intra-adrenal, while about 10%-15% are extra-adrenal, typically along the sympathetic ganglia in the posterior mediastinum [1,2]. Approximately 90% of pheochromocytomas are benign, with the remaining minority being metastatic [1,3-5].

While about 60% of pheochromocytomas are discovered incidentally on abdominal imaging for unrelated reasons, common symptoms for symptomatic patients include episodic headache, sweating, tachycardia, and paroxysmal hypertension [7]. Our patient had no such symptoms prior to his presentation. 

Rarely do patients present with pheochromocytoma multisystem crisis and rapid cyclical fluctuations of hypertension and hypotension. Our patient’s development of cardiomyopathy with global hypokinesis along with the fact that his condition was triggered by receiving the J&J COVID-19 vaccine add further to the uniqueness of this case. Given the large size of his tumor, it is unlikely that the tumor appeared suddenly and caused a pheochromocytoma crisis in our patient. The tumor had most likely been growing for months or even years while the patient remained asymptomatic until something triggered its activity. The J&J COVID-19 vaccine is the only logical trigger as it was given one day before his symptoms began and there were no other inciting factors including medications, drugs, or infection. This sequence of events makes logical sense because vaccines trigger an immune response similar to how an infection would and this likely triggered the activity of the pheochromocytoma. How exactly this occurs remains to be discovered and further studies will be needed to describe this interplay. 

A review of the literature revealed that the adverse events after the J&J vaccine included 14 cerebral venous sinus thrombosis (CVST) cases, three non-CVST thrombocytopenia syndrome, four cases of confirmed anaphylaxis, and 88 reported deaths [17]. Many cases reported no details as to the cause of death but 23 were from cardiac arrest or cardiovascular disease, eight from COVID-19 disease, and five from cerebrovascular disease [17]. There were no reports of anything similar to our patient’s case. There is a report of a pheochromocytoma being triggered by high-dose exogenous steroids and another that describes cases of hypertensive crisis in patients with pheochromocytomas being triggered by certain drugs including rocuronium, pancuronium, and atracurium [18,19].

Upon further review of the literature, there have been 47 cases of pheochromocytoma presenting clinically as shock from 1966-2003 [20]. Certain drugs such as marijuana were used in 30% of patients prior to the onset of shock and our patient used marijuana daily [20]. While this is interesting to note, our patient used marijuana daily, and for the months or years that he had the tumor, it never caused any symptoms. Thus, it is improbable that it triggered a pheochromocytoma crisis on one particular day when it had not done so in the past. The mechanism of shock caused by pheochromocytomas is not fully understood but is thought to be due to hypovolemia from increased capillary permeability or from myocardial injury leading to decreased cardiac output [20]. The possibility of pheochromocytomas secreting interleukin-6 (IL-6) in a paraneoplastic fashion causing an acute inflammatory syndrome has also been reported [21,22]. Levels of IL-6 were not measured in our patient; thus, it is not clear whether this was a contributing factor or not. Our patient presented similarly to those with shock, or an acute inflammatory syndrome as described above, but his symptoms most closely resemble a pheochromocytoma multisystem crisis.

Conclusions

Pheochromocytomas are rare and benign tumors. Most are asymptomatic and rarely present with multisystem organ dysfunction and labile blood pressures when symptoms are present. A pheochromocytoma crisis in previously asymptomatic patients may be triggered by certain medications (such as rocuronium and corticosteroids) or as in our patient, the J&J COVID-19 vaccine. Further studies will be needed to investigate how exactly these medications and the J&J COVID-19 vaccine cause a pheochromocytoma crisis. Diagnosis can be confirmed with significant elevations in biochemical tests and abdominal imaging can localize the tumor for eventual resection. Some pheochromocytomas do not present with classic symptoms of paroxysmal hypertension, episodic headache, sweating, and tachycardia; thus, it is prudent to remain suspicious when patients present with sudden symptoms of multiorgan dysfunction, labile blood pressures, and hyperthermia suggesting the triggering of a previously dormant pheochromocytoma.


References

  1. Bravo EL: Pheochromocytoma: new concepts and future trends. Kidney Int. 1991, 40:544-56. 10.1038/ki.1991.244
  2. Whalen RK, Althausen AF, Daniels GH: Extra-adrenal pheochromocytoma. J Urol. 1992, 147:1-10. 10.1016/s0022-5347(17)37119-7
  3. Plouin PF, Chatellier G, Fofol I, Corvol P: Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension. 1997, 29:1133-9. 10.1161/01.hyp.29.5.1133
  4. Goldstein RE, O'Neill JA Jr, Holcomb GW III, et al.: Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999, 229:755. 10.1097/00000658-199906000-00001
  5. Hamidi O, Young WF Jr, Iñiguez-Ariza NM, et al.: Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab. 2017, 102:3296-305. 10.1210/jc.2017-00992
  6. Stein PP, Black HR: A simplified diagnostic approach to pheochromocytoma: a review of the literature and report of one institution's experience. Medicine. 1991, 70:46-66. 10.1097/00005792-199101000-00004
  7. Gruber LM, Hartman RP, Thompson GB, et al.: Pheochromocytoma characteristics and behavior differ depending on method of discovery. J Clin Endocrinol Metab. 2019, 104:1386-93. 10.1210/jc.2018-01707
  8. Bravo EL: Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev. 1994, 15:356-68. 10.1210/edrv-15-3-356
  9. Baxter MA, Hunter P, Thompson GR, London DR: Phaeochromocytomas as a cause of hypotension. Clin Endocrinol. 1992, 37:304-6. 10.1111/j.1365-2265.1992.tb02326.x
  10. Kakoki K, Miyata Y, Shida Y, et al.: Pheochromocytoma multisystem crisis treated with emergency surgery: a case report and literature review. BMC Res Notes. 2015, 8:758. 10.1186/s13104-015-1738-z
  11. Kassim TA, Clarke DD, Mai VQ, Clyde PW, Mohamed Shakir KM: Catecholamine-induced cardiomyopathy. Endocr Pract. 2008, 14:1137-49. 10.4158/EP.14.9.1137
  12. Ganguly A, Grim CE, Weinberger MH, Henry DP: Rapid cyclic fluctuations of blood pressure associated with an adrenal pheochromocytoma. Hypertension. 1984, 6:281-4.
  13. Oishi S, Sasaki M, Ohno M, Umeda T, Sato T: Periodic fluctuation of blood pressure and its management in a patient with pheochromocytoma. Jpn Heart J. 1988, 29:389-99. 10.1536/ihj.29.389
  14. Park SE: Epidemiology, virology, and clinical features of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2; coronavirus disease-19). Clin Exp Pediatr. 2020, 63:119-124. 10.3345/cep.2020.00493
  15. Li Y, Tenchov R, Smoot J, Liu C, Watkins S, Zhou Q: A comprehensive review of the global efforts on COVID-19 vaccine development. ACS Cent Sci. 2021, 7:512-33. 10.1021/acscentsci.1c00120
  16. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT: Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc. 1983, 58:802-4.
  17. Shay DK, Gee J, Su JR, et al.: Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine — United States, March-April 2021. MMWR Morb Mortal Wkly Rep. 2021, 70:680-684. 10.15585/mmwr.mm7018e2
  18. Ibrahim M, Banga S, Venkatapuram S, Mungee S: Transient cardiogenic shock during a crisis of pheochromocytoma triggered by high-dose exogenous corticosteroids. BMJ Case Rep. 2015, 2015:10.1136/bcr-2014-208683
  19. Jeong CW, Lee HG, Kim WM, Shin SH, Bae HB: Was a hypertensive crisis in a patient with pheochromocytoma caused by rocuronium? A case report. Korean J Anesthesiol. 2009, 57:249-53. 10.4097/kjae.2009.57.2.249
  20. Araújo SA, do Carmo PA, Paulino E Jr, Borges IN, Rocha LO: Pheochromocytoma-induced shock: a case report. Autops Case Rep. 2012, 2:21-30. 10.4322/acr.2012.022
  21. Fukumoto S, Matsumoto T, Harada S, Fujisaki J, Kawano M, Ogata E: Pheochromocytoma with pyrexia and marked inflammatory signs: a paraneoplastic syndrome with possible relation to interleukin-6 production. J Clin Endocrinol Metab. 1991, 73:877-81. 10.1210/jcem-73-4-877
  22. Minetto M, Dovio A, Ventura M, Cappia S, Daffara F, Terzolo M, Angeli A: Interleukin-6 producing pheochromocytoma presenting with acute inflammatory syndrome. J Endocrinol Invest. 2003, 26:453-7. 10.1007/BF03345202

Case report
peer-reviewed

Johnson and Johnson COVID-19 Vaccination Triggering Pheochromocytoma Multisystem Crisis


Author Information

Nahel Haji Jr. Corresponding Author

Internal Medicine, St. Joseph Mercy Oakland Hospital, Pontiac, USA

Sofiah Ali

Internal Medicine, St. Joseph Mercy Oakland Hospital, Pontiac, USA

Emad A. Wahashi

Internal Medicine, St. Joseph Mercy Oakland Hospital, Pontiac, USA

Mahrukh Khalid

Internal Medicine, St. Joseph Mercy Oakland Hospital, Pontiac, USA

Kalyana Ramamurthi

Nephrology, St. Joseph Mercy Oakland Hospital, Pontiac, USA


Ethics Statement and Conflict of Interest Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.



Case report
peer-reviewed

Johnson and Johnson COVID-19 Vaccination Triggering Pheochromocytoma Multisystem Crisis


Figures etc.

SIQ
9.3
RATED BY 2 READERS
CONTRIBUTE RATING

Scholarly Impact Quotient™ (SIQ™) is our unique post-publication peer review rating process. Learn more here.